Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1652

Sort by

Sort Order Select

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood (2025) 145 (26): 3139–3152.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML

Blood blood.2024026113.

https://doi.org/10.1182/blood.2024026113

Published: 2025

Includes: Supplemental data

Journal Articles

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Blood blood.2025028560.

https://doi.org/10.1182/blood.2025028560

Published: 2025

Includes: Supplemental data

Journal Articles

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

Blood blood.2024027540.

https://doi.org/10.1182/blood.2024027540

Published: 2025

Includes: Supplemental data

Journal Articles

Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

Jaclyn Andricovich, Coen Johannes Lap, Alexandros Tzatsos

Blood blood.2024026417.

https://doi.org/10.1182/blood.2024026417

Published: 2025

Includes: Supplemental data

Journal Articles

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Blood (2025) 145 (25): 3041–3051.

https://doi.org/10.1182/blood.2024027543

Published: 2025

Includes: Supplemental data

Journal Articles

PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target

Qingyu Luo, Amanda L. Fortune, Andrew A. Lane

Blood (2025) 145 (25): 2945–2953.

https://doi.org/10.1182/blood.2024027376

Published: 2025

Journal Articles

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood (2025) 145 (25): 3015–3029.

https://doi.org/10.1182/blood.2024027244

Published: 2025

Includes: Supplemental data

Journal Articles

TP53 -mutated acute myeloid leukemia: how can we improve outcomes?

David A. Sallman, Maximilian Stahl

Blood (2025) 145 (24): 2828–2833.

https://doi.org/10.1182/blood.2024024245

Published: 2025

Journal Articles

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old

Roland B. Walter, Victoria Potter, Charles Craddock

Blood (2025) 145 (24): 2847–2856.

https://doi.org/10.1182/blood.2024024247

Published: 2025

Journal Articles

Approaching a therapeutic inflection point for FLT3 -mutated AML

Alexander E. Perl

Blood (2025) 145 (24): 2834–2839.

https://doi.org/10.1182/blood.2024024248

Published: 2025

Journal Articles

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment

Sameem Abedin, Geoffrey L. Uy, Laura C. Michaelis

Blood (2025) 145 (24): 2840–2846.

https://doi.org/10.1182/blood.2024026004

Published: 2025

Journal Articles

Introduction to a Blood Spotlight series on acute myeloid leukemia

Selina M. Luger

Blood (2025) 145 (24): 2801–2802.

https://doi.org/10.1182/blood.2025028384

Published: 2025

Journal Articles

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Blood (2025) 145 (23): 2685–2700.

https://doi.org/10.1182/blood.2024027270

Published: 2025

Includes: Supplemental data

Journal Articles

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

Mark Dalgetty, Jorge Cortes

Blood (2025) 145 (23): 2701–2708.

https://doi.org/10.1182/blood.2024027944

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A , NUP98 , and GLIS2 rearrangements

Grace Egan, Sarah K. Tasian

Blood (2025) 145 (22): 2574–2586.

https://doi.org/10.1182/blood.2024026598

Published: 2025

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

Yanna Ding, Kikkeri N. Naresh

Blood (2025) 145 (22): 2672.

https://doi.org/10.1182/blood.2025028556

Published: 2025

Journal Articles

RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation

Madeline Y Mayday, Giulia Biancon, Manyi Wei, Christian Ramirez, Irene Moratti, Andreas P Pintado-Urbanc, Jether Amos Espinosa, Mi Chen, Lin Wang, Matthew D Simon, Yaara Ofir-Rosenfeld, Oliver Rausch, Toma Tebaldi, Stephanie Halene, Diane S Krause

Blood blood.2024027712.

https://doi.org/10.1182/blood.2024027712

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia

PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

TP53 -mutated acute myeloid leukemia: how can we improve outcomes?

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old

Approaching a therapeutic inflection point for FLT3 -mutated AML

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment

Introduction to a Blood Spotlight series on acute myeloid leukemia

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A , NUP98 , and GLIS2 rearrangements

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only